Pfizer China Announces Leadership Transition as Dr. Wu Xiaobin Departs to Pursue New Ventures, Miao Tianxiang Appointed Successor

Pfizer China announced today (April 23) that Dr. Wu Xiaobin, President of Pfizer’s Core Health Greater China and Country Manager for Pfizer China, will leave the company after 15 years of service to pursue new career opportunities.

Miao Tianxiang, current Vice President of Finance at Pfizer China, will be appointed as President of Pfizer Essential Health Greater China and Country Manager for Pfizer China. Wu Feng, current Head of Commercial and Diversified Businesses in China, will be appointed as Head of Pfizer Essential Health China. These appointments will take effect on May 1, 2018.

“Dr. Wu has led the development of Pfizer’s business in China with focus and integrity, building an outstanding professional organization and establishing a robust compliance culture. His passion, energy, and spirit have inspired many Pfizer employees,” said Huang Weiming, President of Pfizer’s Core Medical Group.

Miao Tianxiang and Wu Feng are both members of the current Pfizer China leadership team. Dr. Wu will work closely with Miao Tianxiang and Wu Feng to ensure a smooth transition.

“Dr. Wu has led the development of Pfizer’s China business with dedication and integrity, building an outstanding professional organization and establishing a robust culture of compliance. Under his leadership, Pfizer China has grown into one of the largest foreign-invested pharmaceutical companies in China, making remarkable contributions to the country’s healthcare sector. By collaborating with industry associations, Dr. Wu has actively helped shape and influence the external environment to ensure that patients in China have access to high-quality medicines and vaccines. His passion, energy, and spirit have inspired many Pfizer employees,” said Huang Weiming, President of Pfizer’s Core Medical Group.

“We sincerely thank Dr. Wu for his strong and steadfast leadership over the years, and wish him every success in his future endeavors—we will all miss him greatly. As experienced leaders, Miao Tianxiang and Wu Feng will continue to lead and contribute to the growth of Pfizer’s business in China,” added Huang Weiming.

Miao Tianxiang is a highly respected leader within the company. His more than 24 years of experience at Pfizer have equipped him with extensive expertise for his roles as President of Greater China and Country Manager.

During his tenure at Pfizer, Miao Tianxiang held a series of increasingly senior roles across multiple divisions, including Animal Health, Manufacturing, and Pharmaceutical Operations. Prior to joining Pfizer, he served as an Associate Professor at Dongbei University of Finance and Economics. In 2014, he was named one of the “Top Ten Outstanding CFOs in China.”

After joining Pfizer in 1998, Wu Feng held a series of key positions, including Head of the Cardiovascular and Cerebrovascular Business Unit, Head of the Anti-Infectives Business Unit, and Head of Commercial Operations in China. Under his leadership, these business segments achieved rapid growth, solidifying Pfizer’s industry-leading position. Wu Feng is widely recognized for his exceptional business acumen, execution capabilities, talent development expertise, and innovative spirit.

As Head of Pfizer Core Medical China, Wu Feng will support the formulation and development of growth strategies for the company’s business in China. He will report to Miao Tianxiang.